This is in agreement with study reporting AKT activation upon MAPK/ERK inhibition, leading to de novo resistance in BRAF-mutant Sk-MEL28 melanoma cells exposed to epidermal growth factor (EGF)53. The gene discussed is BRAF; the disease is melanoma.